James Huang

James Huang is the Founding Managing Partner of Panacea Healthcare Venture Capital and managing partner of Kleiner Perkins China.

He has devoted his passion, diligence, intelligence, and loyalty to the life science and investment industry for over 30 years. He is a successful entrepreneur, investor, and opinion leader in the Venture Capital healthcare sector in China. He focuses on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Prior to that, James was a Managing Partner at Vivo Ventures.

Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. He has also held a number of senior positions across business development, marketing, and R&D functions with world-leading healthcare companies, including Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb, and ALZA Corp. (acquired by Johnson & Johnson).

James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.